Over the past 12 months, 7 insiders at ARS Pharmaceuticals, Inc. filed 9 open-market SEC Form 4 transactions on SPRY: 0 purchases worth $0 and 9 sales worth $3.6M. Insiders have been net sellers over this period. The most recent filing was on Jun 12, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 12, 26 | Alexander A FitzpatrickChief Legal Officer | SELL | 3.4K | $10.00 | $34K |
| Jun 12, 26 | Eric KarasChief Commercial Officer | SELL | 25.0K | $10.00 | $250K |
| Nov 13, 25 | Brian DorseyChief Operating Officer | SELL | 21.8K | $8.71 | $190K |
| Nov 12, 25 | Justin ChakmaChief Business Officer | SELL | 136.4K | $8.91 | $1.2M |
| Aug 21, 25 | Richard E LowenthalPRESIDENT AND CEO | SELL | 50.0K | $14.49 | $725K |
| Aug 21, 25 | Kathleen D. ScottChief Financial Officer | SELL | 12.5K | $15.00 | $188K |
| Aug 20, 25 | Sarina TanimotoCHIEF MEDICAL OFFICER | SELL | 37.7K | $14.09 | $531K |
| Aug 19, 25 | Sarina TanimotoCHIEF MEDICAL OFFICER | SELL | 12.3K | $14.03 | $173K |
| Jul 1, 25 | Eric KarasChief Commercial Officer | SELL | 15.0K | $16.99 | $255K |
| Jun 27, 25 | James E FlynnTenPercentOwner | SELL | 370.1K | $18.46 | $6.8M |
| Jun 18, 25 | Eric KarasChief Commercial Officer | SELL | 15.0K | $16.00 | $240K |
| May 20, 25 | Alexander A FitzpatrickChief Legal Officer | SELL | 103.0K | $14.10 | $1.5M |
| May 20, 25 | Brent L SaundersDirector | SELL | 120.0K | $14.25 | $1.7M |
| May 20, 25 | Kathleen D. ScottChief Financial Officer | SELL | 50.0K | $14.10 | $705K |
| Apr 7, 25 | Laura ShawverDirector | SELL | 50.0K | $12.30 | $615K |
| Mar 20, 25 | Eric KarasChief Commercial Officer | SELL | 10.0K | $14.00 | $140K |
| Mar 6, 25 | Laura ShawverDirector | SELL | 49.6K | $11.21 | $556K |
| Mar 5, 25 | Laura ShawverDirector | SELL | 400 | $11.00 | $4K |
| Feb 3, 25 | Laura ShawverDirector | SELL | 50.0K | $12.31 | $616K |
| Jan 6, 25 | Laura ShawverDirector | SELL | 50.0K | $11.10 | $555K |
| Dec 17, 24 | Richard E LowenthalPRESIDENT AND CEO | SELL | 50.0K | $11.67 | $584K |
| Dec 17, 24 | Sarina TanimotoCHIEF MEDICAL OFFICER | SELL | 50.0K | $11.67 | $584K |
| Dec 13, 24 | Justin ChakmaChief Business Officer | SELL | 27.3K | $12.06 | $329K |
| Dec 12, 24 | Justin ChakmaChief Business Officer | SELL | 117.3K | $12.27 | $1.4M |
| Dec 12, 24 | Brian DorseyChief Operating Officer | SELL | 25.0K | $12.30 | $308K |
| Dec 11, 24 | Brian DorseyChief Operating Officer | SELL | 15.0K | $12.43 | $186K |
| Dec 10, 24 | Justin ChakmaChief Business Officer | SELL | 50.0K | $13.15 | $658K |
| Dec 10, 24 | Richard E LowenthalPRESIDENT AND CEO | SELL | 50.0K | $13.16 | $658K |
| Dec 10, 24 | Sarina TanimotoCHIEF MEDICAL OFFICER | SELL | 50.0K | $13.17 | $659K |
| Dec 6, 24 | Justin ChakmaChief Business Officer | SELL | 50.0K | $14.23 | $712K |
| Dec 5, 24 | Justin ChakmaChief Business Officer | SELL | 49.6K | $14.13 | $701K |
| Dec 4, 24 | Justin ChakmaChief Business Officer | SELL | 45.0K | $13.95 | $628K |
| Dec 4, 24 | Eric KarasChief Commercial Officer | SELL | 6.3K | $14.00 | $88K |
| Dec 4, 24 | Laura ShawverDirector | SELL | 14.8K | $13.75 | $203K |
| Dec 3, 24 | Justin ChakmaChief Business Officer | SELL | 45.0K | $13.19 | $594K |
| Dec 3, 24 | Laura ShawverDirector | SELL | 88.0K | $13.26 | $1.2M |
| Dec 2, 24 | Justin ChakmaChief Business Officer | SELL | 45.0K | $13.67 | $615K |
| Dec 2, 24 | Eric KarasChief Commercial Officer | SELL | 3.7K | $14.11 | $52K |
| Dec 2, 24 | Laura ShawverDirector | SELL | 96.3K | $14.34 | $1.3M |
| Nov 27, 24 | Justin ChakmaChief Business Officer | SELL | 25.0K | $14.39 | $360K |
| Nov 26, 24 | Justin ChakmaChief Business Officer | SELL | 42.2K | $14.05 | $593K |
| Nov 25, 24 | Justin ChakmaChief Business Officer | SELL | 32.8K | $14.00 | $459K |
| Nov 19, 24 | Richard E LowenthalPRESIDENT AND CEO | SELL | 50.0K | $13.95 | $698K |
| Nov 19, 24 | Sarina TanimotoCHIEF MEDICAL OFFICER | SELL | 50.0K | $13.95 | $698K |
| Nov 12, 24 | Richard E LowenthalPRESIDENT AND CEO | SELL | 45.1K | $17.64 | $756K |
| Nov 12, 24 | Sarina TanimotoCHIEF MEDICAL OFFICER | SELL | 45.1K | $17.64 | $756K |
| Nov 12, 24 | Deerfield Private Design Fund Iii, L.p.TenPercentOwner | SELL | 9.6K | $17.77 | $170K |
| Nov 11, 24 | Deerfield Private Design Fund Iii, L.p.TenPercentOwner | SELL | 223.6K | $18.15 | $4.1M |
| Oct 16, 24 | Kathleen D. ScottChief Financial Officer | SELL | 12.5K | $16.00 | $200K |
| Oct 15, 24 | Richard E LowenthalPRESIDENT AND CEO | SELL | 50.0K | $15.25 | $744K |
Over the past 12 months, insiders at ARS Pharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 9 sales worth $3.6M on SPRY, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 12, 26.
7 different insiders at ARS Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on SPRY over the last 12 months.
InsiderTape plots every SPRY insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every ARS Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →